A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms GETUG-AFU22
- 14 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2022.
- 02 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.
- 31 Aug 2018 Biomarkers information updated